ARVN - Arvinas Announces Upcoming Bavdegalutamide Poster Presentation at ESMO Congress 2023 | Benzinga
NEW HAVEN, Conn., Oct. 15, 2023 (GLOBE NEWSWIRE) -- Arvinas, Inc. (NASDAQ:ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced it will present updated Phase 1/2 trial data for bavdegalutamide (ARV-110) at the 2023 European Society for Medical Oncology (ESMO) Annual Congress. Bavdegalutamide is an investigational orally bioavailable PROTAC® androgen receptor (AR) degrader and is being developed as a potential treatment for men with metastatic castration-resistant prostate cancer (mCRPC). This update will be presented during a poster session at the annual congress being held from October 20-24, 2023, in Madrid, Spain.
Poster session details are as follows:
Date: Sunday, October 22, 2023
Time: 12:00 – 1:00 p.m. CEST / 6:00 – 7:00 a.m. EDT
Presentation Number: 1803P
Speaker: Daniel Petrylak, M.D.
- Phase 1/2 study of bavdegalutamide, a PROTAC androgen receptor (AR) degrader, in metastatic castration-resistant prostate cancer (mCRPC): radiographic progression-free survival (rPFS) in patients (pts) with AR ligand-binding domain (LBD) mutations.
For more information, visit the official ESMO Congress website here.
Investor Call & Webcast Details
Arvinas will host a conference and webcast call on Sunday, October 22 at 3 p.m. ...